BITS AND BYTES

Issues 1- 17 / 2008 - 2010

Issue 01, June 2008

• CCN3: A novel function in vivo (A. Leask)
• CCN3-mutant mice are distinct from CCN3-null mice (B. Perbal)

Issue 02, July 2008

• The Starbuck stops here: It's a Smad world (A. Leask)

Issue 03, August 2008

• CCN2 YAPs at cancer (A. Leask)

Issue 04, October 2008

• The Skinny on CCN2 (A. Leask)

Issue 05, November 2008

• Hijacking ZIPcodes: Posttanscriptional regulation of CCN2 by nucleophosin (A. Leask)

Issue 06, January 2009

• Trial by CCN2: a standardized test for fibroproliferative disease? (A. Leask)

Issue 07, February 2009

• Death of a tumor: targeting CCN2 in pancreatic cancer (A. Leask)

Issue 08, March 2009

• What's in an intron ? CCN1 mRNA splicing in cancer (A. Leask)
• Alternative splicing of CCN mRNAs ...It has been upon us (B. Perbal)

Issue 09, April 2009

• Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2 (A. Leask)

Issue 10, August 2009

• Getting to the heart of the matter : CCN2 plays a role in cardiomyocyte hypertrophy (A. Leask)

Issue 11, September 2009

• A sticky situation: CCN1 promotes both proliferation and apoptosis of cancer cells (A. Leask)

Issue 12, November 2009

• Thrombin-induced CCN2 expression as a target for antifibrotic therapy in scleroderma (A. Leask)

Issue 13, February 2010

• It’s a knockout: CCN3 suppresses neointimal thickening (A. Leask)

Issue 14, June 2010

• Yin and Yang part a deux : CCN5 inhibits the pro-fibrotic effects of CCN2 (A. Leask)

Issue 15, August 2010

• When there’s smoke there's.....CCN2(A. Leask)

Issue 16, October 2010

• CCN6 (WISP3): a new anti-cancer therapy ? (A. Leask)

Issue 17, November 2010

• CCN4: new target in osteoarthritis (A. Leask)